Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06140329 · ClinicalTrials.gov registry record
Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation
A clinical trial, sponsored by PYC Therapeutics.
- Terminated
- Registry status
- 1
- Enrollment target
NCT06140329: Clinical Trial study, sponsored by PYC Therapeutics.
NCT06140329 is a clinical trial that was terminated before completion, run by PYC Therapeutics. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06140329 was terminated before completion, sponsored by PYC Therapeutics.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the disease progression of confirmed OPA1 mutation-associated autosomal dominant optic atrophy (ADOA) by evaluating the changes in ocular structural and functional outcomes.
Primary Outcome
Best-corrected high contrast visual acuity (HCVA) for both distance and near will be evaluated using the ETDRS electronic visual acuity charts and the MNRead acuity chart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-02-28 |
| Est. Completion | 2025-03-10 |
Why NCT06140329 stopped before completion
NCT06140329 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT06140329 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06140329 about?
NCT06140329 is a clinical study titled "Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation". The purpose of this study is to characterize the disease progression of confirmed OPA1 mutation-associated autosomal dominant optic atrophy (ADOA) by evaluating the changes in ocular structural and functional outcomes.
What is the current status of trial NCT06140329?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2024-02-28. Estimated completion is 2025-03-10.
Who is sponsoring clinical trial NCT06140329?
This trial is sponsored by PYC Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI